Supriya Lifescience Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹206 Cr +3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
SL

Supriya Lifescience Ltd

Q4 FY26Pharmaceuticals & Biotechnology

SUPRIYA Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹277Cr
+50.5% YoY
+34.5% QoQ
Net profit
₹74Cr
+48% YoY
+48% QoQ
Margin
35%
−2 pp YoY
0 pp QoQ

What the Q4 FY26 call signalled

3 of 4 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising
Price₹928
Market cap₹5.5K Cr
P/E29.9

The short version

- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. - Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.

From Supriya Lifescience Ltd's Q4 FY26 earnings-call transcript · updated 22 Jun 2026.

Revenue & Sales Performance

Good growth
  • Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27.
  • Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD.
  • Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27.
  • Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years.
  • New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth.
  • Backward integration completed to support scalability and cost efficiency.
  • Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27.

2 more points from Supriya Lifescience Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.
  • Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years.
  • Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes.
  • Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Block, and formulation plant needs.

2 more points from Supriya Lifescience Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years.
  • Contracts locked with 3-4 large customers for the cardiovascular product.
  • Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet.
  • DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27.
  • No signed agreement yet for GLP-1 product development; discussions are at an advanced stage.
  • New product launches and existing basket growing steadily.

2 more points from Supriya Lifescience Ltd's call on order book

Create a free account to keep reading this call

Supriya Lifescience Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Supriya Lifescience Ltd Q4 FY26 results — key figures

Supriya Lifescience Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue277184+50.5%206+34.5%
Operating profit (EBITDA)9868+44.1%72+36.1%
Operating margin35%37%-2 pp35%0 pp
Profit before tax9264+43.8%67+37.3%
Net profit (PAT)7450+48%50+48%
EPS (₹)9.226.26+47.3%6.17+49.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹206 Cr, net profit ₹29 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Supriya Lifescience Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Supriya Lifescience Ltd Q1 FY27 results?

- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. - Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27.

What is Supriya Lifescience Ltd share price analysis?

Supriya Lifescience Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 29.9 with a market cap of ₹5,542. Investors should review the full earnings analysis for detailed insights.

Is Supriya Lifescience Ltd planning capital expenditure?

- Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex.

Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.